Accueil Ernstrade Bourse Actualite Stock


Intercell AG (Intercell) is an Austria-based biotechnology company that focuses on the development and manufacturing of vaccines and monoclonal antibodies for the prevention and treatment of infectious diseases. The Company’s technology platforms include an antigen-discovery system, adjuvants and a patch-based delivery system. Intercell’s portfolio consists of one marketed product, eight product candidates in clinical development and additional candidates in pre-clinical development. Its core product is a Japanese Encephalitis vaccine. The focus of the development portfolio of the Company is on nosocomial infections and other selected serious infectious diseases. Its development pipeline includes a Staphylococcus aureus vaccine (P hase II/III); Pseudomonas vaccine (Phase II), and a Pandemic Influenza patch system (Phase I/II), among others. Intercell operates in Austria, Scotland and the United States. It has partnerships with Merck & Co., Novartis, GlaxoSmithKline and sanofi-aventis.
Campus Vienna Biocenter 2
Vienna, 1030
+43-1-206200 (Phone)
+43-1-20620800 (Fax)


Copyright  2011